University of Pennsylvania-Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania 19104
9 studies enrolling now · 33 studies all time
What they study most
AML, Adult T Cell Leukemia/Lymphoma, Advanced Cancer, Advanced Solid Tumor, Anaplastic Thyroid Cancer, Antiphospholipid Syndrome (APS), Behçet's Syndrome (BS), Bilateral Sensorineural Hearing Loss, Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer, Breast Cancer, Bullous Pemphigoid (BP)
Studies at this site
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC — Recruiting now
- Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells — Recruiting now
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma — Recruiting now
- A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors — Recruiting now
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) — Recruiting now
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis — Recruiting now
- A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Recruiting now
- A Global Prospective Observational Registry of Patients With Pompe Disease — Recruiting now
- FTT PET/CT in Pancreatic Neuroendocrine Tumors — Recruiting now
- Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes — Running, not enrolling
- A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC — Starting soon
- Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) — Running, not enrolling
- Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) — Running, not enrolling
- COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders — Stopped early
- A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy — Running, not enrolling
- A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) — Running, not enrolling
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Running, not enrolling
- Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors — Stopped early
- Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer — Completed
- Transthyretin Amyloidosis Outcome Survey (THAOS) — Completed
- Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients — Stopped early
- Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study — Completed
- A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis — Completed
- A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer — Completed
- Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients — Completed
- Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH) — Stopped early
- A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma — Stopped early
- Evaluation of Revised Indicatons (ERID) for Cochlear Implant Candidacy for the Adult CMS Population — Completed
- Plasma-based Colorectal Cancer Screening Research & Development — Completed
- Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects — Completed
- A Safety Study of SGN-CD48A in Patients With Multiple Myeloma — Stopped early
- Safety Study of SGN-CD70A in Cancer Patients — Completed
- Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis — Completed